Immunomedics Company Profile
Immunomedics is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We have recently licensed our lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide. We have retained the rights for epratuzumab in oncology indications for which UCB has been granted a buy-in option. UCB has development, manufacture and commercialization rights, and is responsible for all clinical trials evaluating epratuzumab for the treatment of patients with moderate and severe lupus. At present, there is no cure for lupus and no new lupus drug has been approved in the U.S. in the last 40 years. We believe that our portfolio of intellectual property, which includes approximately 108 patents issued in the United States, and more than 250 other issued patents worldwide, protects our product candidates and technologies. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel dock and lock methodology, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We have transitioned our focus away from the development of diagnostic imaging products in order to accelerate the development of our therapeutic product candidates. Consistent with our de-emphasis on our diagnostic business, we no longer commercialize CEA-Scan®. LeukoScan® will continue to be manufactured and commercialized by us in territories where regulatory approvals have been granted. Furthermore, as of June 30, 2006, research and development into diagnostic product candidates was no longer a material portion of our business.
300 American Road
United States of America
Phone: 973 605 8200
Fax: 973 605 8282
[Immunomedics Inc.] netted $13.2mm through the public sale of 6.1mm common shares at $2.30. The company is developing therapeutic antibodies for cancer and autoimmune diseases.
Immunomedics Inc. (NASDAQ:IMMU) said late Thursday it is planning a follow-on underwritten by Oppenheimer and Cowen. Immunomedics' epratuzumab is in Phase II testing to treat acute lymphoblastic leuke...
Immunomedics Inc. (NASDAQ:IMMU) granted Algeta ASA (OSE:ALGETA) rights to develop a targeted thorium conjugate (TTC) comprised of Algeta's thorium-227, an alpha-particle emitting radionuclide, linked...
Collaboration to Combine Immunomedics' Anti-CD22 Antibody With Algeta's Targeted Thorium Conjugate Platform
[Immunomedics Inc.] netted $15mm through the public sale of 7mm common shares (including the overallotment) at $2.30. The company is developing therapeutic antibodies for cancer and autoimmune disease...
Immunomedics Inc. (NASDAQ:IMMU) raised $14 million through the sale of 6.1 million shares at $2.30 in a follow-on underwritten by Oppenheimer and Cowen. Immunomedics proposed the offering late Thursda...
Summary Website: Immunomedics Headquarters: New Jersey, USA SEC URL: Immunomedics Top BigBiotech ranking*: 43 *Ranking based on reported global biotech sales for year ending December 2011. Ticker sym...
ByPropThink: By Jake King Acquiring non-dilutive capital is always encouraging for a development-stage biotech company, and investors should take note when a company improves its balance sheet witho...
Drugs and Medications
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias.
We have generated hexavalent antibodies (HexAbs) comprising 6 Fabs tethered to one Fc of human IgG1. Three such constructs: 20-20, a monospecific HexAb comprising 6 Fabs of veltuzumab (humanized anti-...
Immunomedics is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseas...
More Information about "Immunomedics" on BioPortfolio
We have published hundreds of Immunomedics news stories on BioPortfolio along with dozens of Immunomedics Clinical Trials and PubMed Articles about Immunomedics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Immunomedics Companies in our database. You can also find out about relevant Immunomedics Drugs and Medications on this site too.